The Value of FENO Measurement for Predicting Treatment Response in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Aiyuan Zhou,Zijing Zhou,Dingding Deng,Yiyang Zhao,Jiaxi Duan,Wei Cheng,Cong Liu,Ping Chen
DOI: https://doi.org/10.2147/COPD.S263673
2020-09-26
International Journal of COPD
Abstract:Aiyuan Zhou, 1, 2 Zijing Zhou, 1, 2 Dingding Deng, 3 Yiyang Zhao, 1, 2 Jiaxi Duan, 1, 2 Wei Cheng, 1, 2 Cong Liu, 1, 2 Ping Chen 1, 2 1 Department of Respiratory Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, People's Republic of China; 2 Research Unit of Respiratory Disease, Central South University, Changsha, Hunan 410011, People's Republic of China; 3 Department of Respiratory Medicine, The First Affiliated People's Hospital, Shaoyang College, Shaoyang, Hunan 422000, People's Republic of China Correspondence: Ping Chen Department of Respiratory Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, People's Republic of China Email pingchen0731@csu.edu.cn Background: Fractional exhaled nitric oxide (FENO) has been shown to be a marker of airway inflammation in various pulmonary diseases, including chronic obstructive pulmonary disease (COPD). In this study, we assessed the FENO level in patients with acute exacerbations of COPD (AECOPD) and analyzed the predictive value of the FENO level for treatment response. Methods: Demographic data were collected at admission. FENO, lung function, blood gases, COPD Assessment Test (CAT), and modified Medical Research Council (mMRC) scores were measured at admission and on day 7. At the second visit, the patients were asked to report their health status; scores ranged from 1 to 5, representing "much better", "slightly better", "no change", "slightly worse", and "much worse", respectively. The treatment response was evaluated based on the patient's reported health status (responders were those who reported much better and slightly better) and lung function (responders were those who presented an increase in FEV 1 over 200 mL). Results: A total of 182 patients were recruited into the analysis. The FENO level positively correlated with an increase in FEV 1 and FEV 1 % (r = 0.291, p < 0.001 and r = 0.205, p = 0.005, respectively), but negatively correlated with a decrease in the COPD Assessment Test (CAT) score (r = − 0.197, p = 0.008) and patient-reported health status (rho = − 0.408, p< 0.001). An inverse correlation was observed between FENO concentrations at admission and the length of hospital stay. The cut-off point for differentiating responders, identified by health status, was 18 ppb, with the sensitivity being 89.7% and specificity 88.9%. Conclusion: FENO levels, determined at hospital admission, are potential to predict the overall treatment response in AECOPD patients, including remission in subjective patient-reported health statuses and, also, improvements in lung function. Registry Number: ChiCTR-ROC-16,009,087 ( http://www.chictr.org.cn/ ). Keywords: COPD, exacerbation, FENO, lung function, treatment response